USANA's Kevin Guest Advocates Growth Mindset for 2026 Success
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 05 2026
0mins
Source: PRnewswire
- Growth Mindset Advocacy: Kevin Guest, Executive Chairman of USANA Health Sciences, emphasizes that embracing a growth mindset is crucial for achieving lasting success, particularly as leaders and teams in the company's 25 operational countries can see significant results in both professional and personal development.
- Experience and Lessons Shared: In his bestselling book, All the Right Reasons, Guest reflects on a pivotal financial loss early in his career, highlighting how painful experiences can reshape decision-making processes, thereby fostering personal growth and business success.
- Commitment to Social Responsibility: Proceeds from each sale of All the Right Reasons provide 40 meals to the USANA Foundation, which has delivered over 112 million meals to hungry children, showcasing the company's dedication to social responsibility and purposeful growth.
- Leadership Principles Dissemination: Guest shares four initial strategies aimed at enhancing mindset, promoting the cultivation of leadership, integrity, and purpose, further solidifying USANA's leadership position in the health and nutrition product sector.
Get Free Real-Time Notifications for Any Stock
Monitor tickers like USNA with instant alerts to capture every critical market movement.
Sign up for free to build your custom watchlist and receive professional-grade stock notifications.
Analyst Views on USNA
Wall Street analysts forecast USNA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for USNA is 39.00 USD with a low forecast of 39.00 USD and a high forecast of 39.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Analyst Rating
0 Buy
1 Hold
0 Sell
Hold
Current: 21.370
Low
39.00
Averages
39.00
High
39.00
Current: 21.370
Low
39.00
Averages
39.00
High
39.00
About USNA
USANA Health Sciences, Inc. and subsidiaries is a global nutrition, personal health and wellness company that develops and manufactures science-based nutritional and personal care products. Its segments include Direct selling and Hiya direct-to-consumer. The Direct Selling segment develops and manufactures science-based nutritional, personal care and skincare products with a primary focus on promoting long-term health and wellness in various geographic markets worldwide that are distributed through the direct selling channel. The Hiya direct-to-consumer segment is a provider of children’s health and wellness products in the United States that are distributed through the direct-to-consumer channel. Its product line includes USANA Nutritionals Optimizers, Essentials/CellSentials, and Foods. USANA Nutritionals Optimizers products include Proflavanol, CoQuinone 30, and BiOmega-3. Essentials/CellSentials products include USANA CellSentials and HealthPak 100.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Doseology Sciences Partners with McKinney to Enhance Regulatory Compliance
- Strategic Partnership: Doseology has formed a strategic partnership with McKinney Regulatory Science Advisors to enhance its regulatory compliance capabilities, ensuring product development meets stringent FDA requirements, thereby accelerating market entry and strengthening competitiveness.
- Market Outlook: The global pouch market is projected to exceed $69.46 billion by 2032, and through its collaboration with McKinney, Doseology aims to secure a leading position in this rapidly growing market, driving the commercialization of its innovative oral products.
- Compliance Advantage: McKinney will provide Doseology with comprehensive regulatory guidance, including PMTA preparation and post-market compliance, ensuring its products gain approval in a complex regulatory environment, thus reducing market access risks.
- Science-Driven Approach: Doseology is committed to a science and innovation-driven strategy, ensuring its products not only meet consumer demands but also gain regulatory recognition, thereby establishing a sustainable business model in a competitive market.
Continue Reading
Doseology Sciences Partners with McKinney to Enhance Regulatory Compliance
- Market Potential: The global consumer healthcare market is projected to reach $362.17 billion by 2026, and Doseology is enhancing its regulatory compliance capabilities through a partnership with McKinney Regulatory Science Advisors, thereby strengthening its competitive position in this landscape.
- Strategic Collaboration: The partnership with McKinney will encompass formulation strategy, data generation, and PMTA preparation, ensuring that Doseology's product development is not only innovative but also aligned with regulatory expectations, laying the groundwork for entry into a global pouch market expected to exceed $69.46 billion.
- Clear Regulatory Pathway: McKinney's expert guidance will assist Doseology in expediting market access under FDA requirements while strengthening intellectual property protection through aligned formulation and testing strategies, ensuring its products stand out in a competitive market.
- Leadership Team Enhancement: Doseology has appointed Patrick Sills, a former executive from Swedish Match and Philip Morris International, as its commercial leader, combining a robust regulatory strategy with secured manufacturing infrastructure to propel the company towards market entry, showcasing strong growth potential.
Continue Reading